Canada · updated July 2026
Generic semaglutide in Canada, plainly explained
In the spring of 2026, Canada became the first G7 country to approve a generic version of semaglutide — the medicine behind Ozempic and Wegovy. Here's what was approved, what it costs, and what public plans do and don't cover. No advice, just the lay of the land.
What actually changed
Generic drugs usually can't launch until the original maker's patents expire. In Canada, a key semaglutide patent lapsed early — Novo Nordisk did not keep it in force — which opened the door years ahead of the United States and Europe. The result: Canadians now have lower-cost generic options that most other countries won't see for years.
The generics approved so far
Three approvals have landed, and Health Canada has said several more are in the queue.
Dr. Reddy's generic semaglutide
Apr 28, 2026
The first generic approved — a version of Ozempic for type 2 diabetes, in 2 mg and 4 mg pens. Sold as generic semaglutide rather than under a brand name.
Apo-Semaglutide (Apotex)
May 1, 2026
A Canadian-made generic of Ozempic for type 2 diabetes, in the same 2 mg and 4 mg pen formats. This is the version many pharmacies stocked first.
Sevmia (Apotex)
Jun 29, 2026
Canada's first generic semaglutide approved for chronic weight management — the generic counterpart to Wegovy, cleared for adults and adolescents 12 and older who meet the criteria.
Health Canada has said around six more generic semaglutide submissions are under review, with decisions expected through 2026.
What it costs
The headline is price. Generic semaglutide launched at roughly a third of brand-name Ozempic's cash price. These are self-pay figures from mid-2026 and will keep moving — always confirm with your own pharmacy.
Roughly, per month
Costco listed the generic pen near $88 in Ontario and BC, a little higher in Alberta and Quebec. Prices vary by pharmacy, province, and over time.
What's covered
Coverage is the fine print most people miss. Broadly, public drug plans across Canada cover semaglutide for type 2 diabetes — with conditions — and generally do not cover it for weight loss.
Diabetes (Ozempic / generic)
Typically covered with restrictions. Ontario's ODB looks for type 2 diabetes not well controlled on metformin; BC PharmaCare needs Special Authority; Quebec's RAMQ asks a physician to attest that earlier therapy fell short. Generic listing status on each formulary is still settling in.
Weight management (Wegovy / Sevmia)
Generally not on public formularies. Most people pay out of pocket or rely on private insurance, and coverage varies plan by plan.
Your pharmacist can check your exact plan and whether a generic substitution applies to your prescription.
Switching pens, not starting over
If you move from a brand pen to a generic, your dose and your history are still yours. Light Years is a calm place to log each dose and watch your real trend — nothing louder than it needs to be.
Open Light Years